Effective today, ORC 4729.531 allows a wild animal rehabilitation facility to obtain from the Ohio Board of Pharmacy a limited terminal distributor of dangerous drugs (TDDD) license. For more information, visit: www.pharmacy.ohio.gov/WARF.
The Ohio Board of Pharmacy encourages all healthcare professionals who may be struggling with a substance use disorder or mental health condition to seek help. For more information, visit: www.pharmacy.ohio.gov/Recovery
The Board is now accepting applications for an appointment to the Home Medical Equipment (HME) Services Advisory Council, which advises the Board on issues relating to providing HME services. For more information, visit: www.pharmacy.ohio.gov/HMEapplication.
In addition to free fentanyl test strips and naloxone brochures, the Board is now offering free xylazine test strips to all Ohio licensees. To place an order, licensees located in the state of Ohio can visit: www.pharmacy.ohio.gov/FTSorder
The Ohio Board of Pharmacy is requesting comments for their Electronic Product Verification rule package. Comments are due on 2/20/2026. To review the rule and for instructions on how to comment, visit: www.pharmacy.ohio.gov/EPVrule
The Board of Pharmacy has announced the dates and topics for the 2026 Law and Responsible Person Review Virtual Presentations. For more information, including a link to sign up, visit: www.pharmacy.ohio.gov/lawreview.
The Board recently approved a resolution permitting the transmission of prescriptions for compounded total parenteral nutrition for dispensation by a pharmacy via an electronic system that converts the prescription into a computer-generated fax or scanned image.
Effective January 15, 2027, OAC 4729:5-5-04 will require, with limited exceptions, that all Ohio outpatient pharmacies adopt electronic positive identification as part of the pharmacy’s record keeping system. For more information, visit: www.pharmacy.ohio.gov/waiver.
Section 4729.45 of the Revised Code and recent updates to OAC rule 4729:1-3-03 authorize a pharmacist to administer, by subcutaneous or intramuscular injection, any of the dangerous drugs listed here. For more information, visit: www.pharmacy.ohio.gov/administration.
10. Expired/Adulterated Drugs in Active Drug Stock. OAC 4729:5-3-06 requires adulterated or expired drugs to be stored in a separate and secure area apart from the storage of drugs used for dispensing, personally furnishing, compounding, and administration.
9. Labeling Multi-Dose Vials. Upon the initial puncture of a multiple-dose vial containing a drug, the vial shall be labeled with a beyond-use date or date opened. A multiple-dose vial that exceeds its beyond-use date shall be deemed adulterated.
The Ohio Board of Pharmacy is requesting comments for their Mitragynine and Mitragynine-Related Compounds rule packages. Comments are due on 1/28/2026. To review the rules and for instructions on how to comment, visit: www.pharmacy.ohio.gov/mitragynine and www.pharmacy.ohio.gov/mitragyninecompounds.
8. Patient-Specific Drugs Used as Office-Stock (Pick-Up Station). Patient-specific drugs dispensed by a pharmacy are the property of the patient and cannot be administered to other persons. This is a violation of both federal and state law.
7. Inadequate Record Keeping. Remember, a licensee must maintain temperature logs or have a temperature monitoring system for drugs stored in refrigerators and freezers that complies with OAC 4729:5-19-03.
6. Failure to Secure Controlled Substances. OAC 4729:5-19-03 prohibits unlicensed persons from having access to controlled substances (both patient-specific and inventory). This includes testosterone.
5. Failure to Comply with Compounding Standards. Some common violations include drawing up or repackaging syringes of compounded or reconstituted drugs for at-home administration and failure of a prescriber to verify a compounded drug product prior to administration.
4. Purchasing Non-FDA Approved Medications Including Foreign-Sourced Drugs or Drugs Not Permitted for Compounding. Any drugs with foreign labeling or any indication they are intended for foreign markets must be disposed of immediately.
3. Insanitary Preparation of Medications Marked “Unfinished Drug Products” or Active Pharmaceutical Ingredients (API). All preparation of unfinished drug products or API is considered compounding and must comply with OAC 4729:7-3 and the applicable USP chapters.
This holiday season, the Ohio Board of Pharmacy would like to remind you that mistletoe extract for injection is not authorized by the Food and Drug Administration (FDA) for use in the United States. Selling or using mistle extract for injection is a violation of federal law.
2. Purchasing Medications Marked “For Research Purposes Only (RUO)”. The most commonly found RUO drugs include GLP-1s (ex. semaglutide, tirzepatide, retatrutide, cagrilinitde). These medications cannot be used in compounding under federal and state law.
1. Purchasing from Unlicensed Sellers. Licensees cannot purchase drugs from social media sites, internet sellers (unless licensed by OBP), and other clinics or prescribers, unless they are under the same ownership or going through a discontinuation of business.
The Board has resources to assist licensees with this information, including inspection guides, guidance documents, and a more detailed explanation of the violations at www.pharmacy.ohio.gov/top10. Still have questions? Email contact@pharmacy.ohio.gov or call 614-466-4143.
Over the next few weeks, the Ohio Board of Pharmacy is highlighting 10 common violations identified at prescriber clinics and med spas to educate current and future licensees. For more information on these violations and links to Board rules, visit: www.pharmacy.ohio.gov/top10.
The Board wants to remind licensees to verify their seller to ensure they are authorized to sell in Ohio and are licensed by the Ohio Board of Pharmacy. You can verify a seller by visiting: www.elicense.ohio.gov.
The Ohio Board of Pharmacy has released its FY 2025 Annual Report. The report can be accessed here: www.pharmacy.ohio.gov/FY2025Report.
Starting February 4, 2026, Ohio TDDD licensure from the Board will be required for all entities engaged in phase 2 or 3 clinical trials of an investigational new drug or product. For more information, visit: www.pharmacy.ohio.gov/IND
Check out this quarter's OARRS e-newsletter using the link below⬇️ www.pharmacy.ohio.gov/documents/pu...
Note that this ban does not apply to kratom products that contain only mitragynine (such as natural kratom in its vegetation form). For more information and a list of frequently asked questions, visit: pharmacy.ohio.gov/7OHnotice
Consumer and Retailer Notice: Kratom-related products are now illegal in Ohio, except for products composed solely of mitragynine. For more information, visit: pharmacy.ohio.gov/7OHnotice
Check out December's e-newsletter using the link below⬇️ www.pharmacy.ohio.gov/documents/pu...
